Update date
31 Dec 2025
Shareable Research Card
This metric view shows STLA - Stellantis N.V. research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest reported research and development expense: €11,145,000,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Update date
31 Dec 2025
Page type
Metric history
Latest period
2025
SEC-backed company facts were refreshed from filings filed on 26 Feb 2026.
Benchmark Context
Stellantis N.V. sits in the top quarter of the current research and development expense sample.
Compared with
Compared with 57 companies reporting research and development expense in EUR. This keeps the comparison on the same metric and unit family.
Why this is notable
That is about 251x the current visible midpoint. Research And Development Expense is up about 93% versus the comparable prior period.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Latest period: 2025. Period end: 31 Dec 2025. Units: EUR. Frequency: annual and quarterly.
Research And Development Expense is an SEC-reported metric from company XBRL facts.
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Stellantis N.V. appears at rank #1 in the latest comparison sample.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Stellantis N.V. (stla) | €11,145,000,000 | Year - 31 Dec 2025 | Open Stellantis N.V. Research And Development Expense |
| 2 | Sanofi (sny) | €7,842,000,000 | Year - 31 Dec 2025 | Open Sanofi Research And Development Expense |
| 3 | SAP SE (sap) | €6,633,000,000 | Year - 31 Dec 2025 | Open SAP SE Research And Development Expense |
| 4 | NOKIA CORP (nok) | €4,855,000,000 | Year - 31 Dec 2025 | Open NOKIA CORP Research And Development Expense |
| 5 | BioNTech SE (bntx) | €2,104,900,000 | Year - 31 Dec 2025 | Open BioNTech SE Research And Development Expense |
| 6 | KONINKLIJKE PHILIPS NV (phg) | €1,700,000,000 | Year - 31 Dec 2025 | Open KONINKLIJKE PHILIPS NV Research And Development Expense |
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | €11,145,000,000 | +€5,361,000,000 | +93% | 01 Jan 2025 | 31 Dec 2025 | 20-F | 26 Feb 2026 | 2025 | FY |
| 2024 | €5,784,000,000 | +€165,000,000 | +2.9% | 01 Jan 2024 | 31 Dec 2024 | 20-F | 26 Feb 2026 | 2025 | FY |
| 2023 | €5,619,000,000 | +€419,000,000 | +8.1% | 01 Jan 2023 | 31 Dec 2023 | 20-F | 26 Feb 2026 | 2025 | FY |
| 2022 | €5,200,000,000 | +€713,000,000 | +16% | 01 Jan 2022 | 31 Dec 2022 | 20-F | 27 Feb 2025 | 2024 | FY |
| 2021 | €4,487,000,000 | +€2,256,000,000 | +101% | 01 Jan 2021 | 31 Dec 2021 | 20-F | 22 Feb 2024 | 2023 | FY |
| 2020 | €2,231,000,000 | -€342,000,000 | -13% | 01 Jan 2020 | 31 Dec 2020 | 20-F | 24 Feb 2023 | 2022 | FY |
| 2019 | €2,573,000,000 | -€478,000,000 | -16% | 01 Jan 2019 | 31 Dec 2019 | 20-F | 25 Feb 2022 | 2021 | FY |
| 2018 | €3,051,000,000 | +€148,000,000 | +5.1% | 01 Jan 2018 | 31 Dec 2018 | 20-F | 04 Mar 2021 | 2020 | FY |
| 2017 | €2,903,000,000 | -€27,000,000 | -0.92% | 01 Jan 2017 | 31 Dec 2017 | 20-F | 25 Feb 2020 | 2019 | FY |
| 2016 | €2,930,000,000 | +€66,000,000 | +2.3% | 01 Jan 2016 | 31 Dec 2016 | 20-F | 22 Feb 2019 | 2018 | FY |
| 2015 | €2,864,000,000 | 01 Jan 2015 | 31 Dec 2015 | 20-F | 20 Feb 2018 | 2017 | FY |
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2020 | €576,000,000 | -€206,000,000 | -26% | 01 Apr 2020 | 30 Jun 2020 | 6-K/A | 23 Sep 2020 | 2020 | Q2 | |
| Q2 2019 | €782,000,000 | 01 Apr 2019 | 30 Jun 2019 | 6-K/A | 23 Sep 2020 | 2020 | Q2 |